

**CHANGES TO THE COMPOSITION OF THE BOARD COMMITTEES OF THE COMPANY**

---

The Board of Directors (the “**Board**”) of Biolidics Limited (the “**Company**”) wishes to announce that, following the appointment of Mr Ian David Brown as an Independent Director of the Company on 14 June 2021, Mr Ian David Brown has been appointed as a member of the Nominating Committee, Audit Committee (“**AC**”) and Remuneration Committee of the Company, with effect from 21 June 2021.

In respect of Mr Ian David Brown’s appointment to the AC, he is considered independent for the purposes of Rule 704(7) of the Singapore Exchange Securities Trading Limited’s (“**SGX-ST**”) Listing Manual Section B: Rules of Catalist.

Consequent to the aforesaid changes, the composition of the Board Committees of the Company comprises the following members:

Audit Committee

Kong Chee Keong	- Chairman
Chia Beng Kwan	- Member
Leong Yow Seng	- Member
Ian David Brown	- Member

Nominating Committee

Chia Beng Kwan	- Chairman
Chen Johnson	- Member
Leong Yow Seng	- Member
Ian David Brown	- Member

Remuneration Committee

Leong Yow Seng	- Chairman
Yee Pinh Jeremy	- Member
Kong Chee Keong	- Member
Ian David Brown	- Member

**BY ORDER OF THE BOARD**

Yee Pinh Jeremy  
Non-Executive Non-Independent Chairman  
21 June 2021

---

*This announcement has been prepared by the Company and has been reviewed by United Overseas Bank Limited (the “**Sponsor**”) for compliance with Rules 226(2)(b) and 753(2) of the SGX-ST Listing Manual Section B: Rules of Catalist.*

*This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr. Lim Hoon Khia, Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*